[Market Focus] AJU IB Investment Soars 30% on Hopes for Investment Returns
The stock price of AJU IB Investment, a venture capital (VC) firm, surged on heightened expectations for global bio investment returns.
As of 10:03 a.m. on February 27, AJU IB Investment was trading at 5,810 won, up 1,340 won (29.98%) from the previous day.
According to foreign media reports the previous day, global pharmaceutical company Gilead has agreed to acquire Axcella Therapeutics, a bio company invested in by Solasta Ventures, for 7.8 billion dollars (about 10 trillion won). Axcella Therapeutics is a company invested in by Solasta Ventures, the U.S. subsidiary of AJU IB Investment.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
AJU IB Investment has been divesting from Axcella Therapeutics since its listing on the NASDAQ in 2023 and into last year. It is known that the company still holds a significant portion of shares. AJU IB Investment expects an investment multiple of up to 9 times its original principal.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.